Global Non-muscle Invasive Bladder Cancer Therapeutics Supply, Demand and Key Producers, 2023-2029
Page: 131
Published Date: 23 Mar 2023
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags
Description
The global Non-muscle Invasive Bladder Cancer Therapeutics market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Non-muscle Invasive Bladder Cancer Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Non-muscle Invasive Bladder Cancer Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Non-muscle Invasive Bladder Cancer Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Non-muscle Invasive Bladder Cancer Therapeutics total market, 2018-2029, (USD Million)
Global Non-muscle Invasive Bladder Cancer Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Non-muscle Invasive Bladder Cancer Therapeutics total market, key domestic companies and share, (USD Million)
Global Non-muscle Invasive Bladder Cancer Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Non-muscle Invasive Bladder Cancer Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Non-muscle Invasive Bladder Cancer Therapeutics total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Non-muscle Invasive Bladder Cancer Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Non-muscle Invasive Bladder Cancer Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, Segmentation by Type
Intravesical Chemotherapy
Intravesical Immunotherapy
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, Segmentation by Application
Hospital
Ambulatory Surgery Center
Others
Companies Profiled:
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
Key Questions Answered
1. How big is the global Non-muscle Invasive Bladder Cancer Therapeutics market?
2. What is the demand of the global Non-muscle Invasive Bladder Cancer Therapeutics market?
3. What is the year over year growth of the global Non-muscle Invasive Bladder Cancer Therapeutics market?
4. What is the total value of the global Non-muscle Invasive Bladder Cancer Therapeutics market?
5. Who are the major players in the global Non-muscle Invasive Bladder Cancer Therapeutics market?
6. What are the growth factors driving the market demand?
Table of Contents
1 Supply Summary
1.1 Non-muscle Invasive Bladder Cancer Therapeutics Introduction
1.2 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Non-muscle Invasive Bladder Cancer Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.3 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.5 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.6 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.3.8 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Non-muscle Invasive Bladder Cancer Therapeutics Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2.1 World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.2 World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value by Region
2.2.1 World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.4 China Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.5 Europe Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.6 Japan Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.7 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
2.9 India Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029)
3.1 World Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Non-muscle Invasive Bladder Cancer Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Non-muscle Invasive Bladder Cancer Therapeutics in 2022
3.3 Non-muscle Invasive Bladder Cancer Therapeutics Company Evaluation Quadrant
3.4 Non-muscle Invasive Bladder Cancer Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Non-muscle Invasive Bladder Cancer Therapeutics Market: Region Footprint
3.4.2 Non-muscle Invasive Bladder Cancer Therapeutics Market: Company Product Type Footprint
3.4.3 Non-muscle Invasive Bladder Cancer Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Non-muscle Invasive Bladder Cancer Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Non-muscle Invasive Bladder Cancer Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023)
5.1 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Intravesical Chemotherapy
5.2.2 Intravesical Immunotherapy
5.3 Market Segment by Type
5.3.1 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2018-2023)
5.3.2 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2024-2029)
5.3.3 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2018-2029)
6.1 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Ambulatory Surgery Center
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2018-2023)
6.3.2 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2024-2029)
6.3.3 World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2018-2029)
7.1 F. Hoffmann-La Roche Ltd.
7.1.1 F. Hoffmann-La Roche Ltd. Details
7.1.2 F. Hoffmann-La Roche Ltd. Major Business
7.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
7.1.6 F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Details
7.2.2 Bristol-Myers Squibb Company Major Business
7.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
7.2.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
7.3 AstraZeneca
7.3.1 AstraZeneca Details
7.3.2 AstraZeneca Major Business
7.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 AstraZeneca Recent Developments/Updates
7.3.6 AstraZeneca Competitive Strengths & Weaknesses
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Details
7.4.2 Pfizer Inc. Major Business
7.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Pfizer Inc. Recent Developments/Updates
7.4.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.5 GlaxoSmithKline plc.
7.5.1 GlaxoSmithKline plc. Details
7.5.2 GlaxoSmithKline plc. Major Business
7.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 GlaxoSmithKline plc. Recent Developments/Updates
7.5.6 GlaxoSmithKline plc. Competitive Strengths & Weaknesses
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Details
7.6.2 Sanofi S.A. Major Business
7.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Sanofi S.A. Recent Developments/Updates
7.6.6 Sanofi S.A. Competitive Strengths & Weaknesses
7.7 Novartis AG
7.7.1 Novartis AG Details
7.7.2 Novartis AG Major Business
7.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis AG Recent Developments/Updates
7.7.6 Novartis AG Competitive Strengths & Weaknesses
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Details
7.8.2 Eli Lilly and Company Major Business
7.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Eli Lilly and Company Recent Developments/Updates
7.8.6 Eli Lilly and Company Competitive Strengths & Weaknesses
7.9 Merck & Co.
7.9.1 Merck & Co. Details
7.9.2 Merck & Co. Major Business
7.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Merck & Co. Recent Developments/Updates
7.9.6 Merck & Co. Competitive Strengths & Weaknesses
7.10 Viventia Bio Inc.
7.10.1 Viventia Bio Inc. Details
7.10.2 Viventia Bio Inc. Major Business
7.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Viventia Bio Inc. Recent Developments/Updates
7.10.6 Viventia Bio Inc. Competitive Strengths & Weaknesses
7.11 Celgene Corporation
7.11.1 Celgene Corporation Details
7.11.2 Celgene Corporation Major Business
7.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Celgene Corporation Recent Developments/Updates
7.11.6 Celgene Corporation Competitive Strengths & Weaknesses
7.12 Spectrum Pharmaceuticals, Inc.
7.12.1 Spectrum Pharmaceuticals, Inc. Details
7.12.2 Spectrum Pharmaceuticals, Inc. Major Business
7.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments/Updates
7.12.6 Spectrum Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.13 Herantis Pharma Plc.
7.13.1 Herantis Pharma Plc. Details
7.13.2 Herantis Pharma Plc. Major Business
7.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Herantis Pharma Plc. Recent Developments/Updates
7.13.6 Herantis Pharma Plc. Competitive Strengths & Weaknesses
7.14 Taris Biomedical LLC
7.14.1 Taris Biomedical LLC Details
7.14.2 Taris Biomedical LLC Major Business
7.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Taris Biomedical LLC Recent Developments/Updates
7.14.6 Taris Biomedical LLC Competitive Strengths & Weaknesses
7.15 Prometic Life Sciences Inc.
7.15.1 Prometic Life Sciences Inc. Details
7.15.2 Prometic Life Sciences Inc. Major Business
7.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Prometic Life Sciences Inc. Recent Developments/Updates
7.15.6 Prometic Life Sciences Inc. Competitive Strengths & Weaknesses
7.16 Telormediz S.A.
7.16.1 Telormediz S.A. Details
7.16.2 Telormediz S.A. Major Business
7.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Telormediz S.A. Recent Developments/Updates
7.16.6 Telormediz S.A. Competitive Strengths & Weaknesses
7.17 Heat Biologics
7.17.1 Heat Biologics Details
7.17.2 Heat Biologics Major Business
7.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Heat Biologics Recent Developments/Updates
7.17.6 Heat Biologics Competitive Strengths & Weaknesses
7.18 Altor BioScience
7.18.1 Altor BioScience Details
7.18.2 Altor BioScience Major Business
7.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Altor BioScience Recent Developments/Updates
7.18.6 Altor BioScience Competitive Strengths & Weaknesses
7.19 Ferring B.V.
7.19.1 Ferring B.V. Details
7.19.2 Ferring B.V. Major Business
7.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.19.5 Ferring B.V. Recent Developments/Updates
7.19.6 Ferring B.V. Competitive Strengths & Weaknesses
7.20 Cold Genesys Inc.
7.20.1 Cold Genesys Inc. Details
7.20.2 Cold Genesys Inc. Major Business
7.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
7.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.20.5 Cold Genesys Inc. Recent Developments/Updates
7.20.6 Cold Genesys Inc. Competitive Strengths & Weaknesses
8.1 Non-muscle Invasive Bladder Cancer Therapeutics Industry Chain
8.2 Non-muscle Invasive Bladder Cancer Therapeutics Upstream Analysis
8.3 Non-muscle Invasive Bladder Cancer Therapeutics Midstream Analysis
8.4 Non-muscle Invasive Bladder Cancer Therapeutics Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Non-muscle Invasive Bladder Cancer Therapeutics Players in 2022
Table 12. World Non-muscle Invasive Bladder Cancer Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Non-muscle Invasive Bladder Cancer Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Non-muscle Invasive Bladder Cancer Therapeutics Player
Table 15. Non-muscle Invasive Bladder Cancer Therapeutics Market: Company Product Type Footprint
Table 16. Non-muscle Invasive Bladder Cancer Therapeutics Market: Company Product Application Footprint
Table 17. Non-muscle Invasive Bladder Cancer Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Non-muscle Invasive Bladder Cancer Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Non-muscle Invasive Bladder Cancer Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share (2018-2023)
Table 29. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. F. Hoffmann-La Roche Ltd. Basic Information, Area Served and Competitors
Table 36. F. Hoffmann-La Roche Ltd. Major Business
Table 37. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 38. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 40. F. Hoffmann-La Roche Ltd. Competitive Strengths & Weaknesses
Table 41. Bristol-Myers Squibb Company Basic Information, Area Served and Competitors
Table 42. Bristol-Myers Squibb Company Major Business
Table 43. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 44. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Bristol-Myers Squibb Company Recent Developments/Updates
Table 46. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
Table 47. AstraZeneca Basic Information, Area Served and Competitors
Table 48. AstraZeneca Major Business
Table 49. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 50. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. AstraZeneca Recent Developments/Updates
Table 52. AstraZeneca Competitive Strengths & Weaknesses
Table 53. Pfizer Inc. Basic Information, Area Served and Competitors
Table 54. Pfizer Inc. Major Business
Table 55. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 56. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Pfizer Inc. Recent Developments/Updates
Table 58. Pfizer Inc. Competitive Strengths & Weaknesses
Table 59. GlaxoSmithKline plc. Basic Information, Area Served and Competitors
Table 60. GlaxoSmithKline plc. Major Business
Table 61. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 62. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. GlaxoSmithKline plc. Recent Developments/Updates
Table 64. GlaxoSmithKline plc. Competitive Strengths & Weaknesses
Table 65. Sanofi S.A. Basic Information, Area Served and Competitors
Table 66. Sanofi S.A. Major Business
Table 67. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 68. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Sanofi S.A. Recent Developments/Updates
Table 70. Sanofi S.A. Competitive Strengths & Weaknesses
Table 71. Novartis AG Basic Information, Area Served and Competitors
Table 72. Novartis AG Major Business
Table 73. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 74. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Novartis AG Recent Developments/Updates
Table 76. Novartis AG Competitive Strengths & Weaknesses
Table 77. Eli Lilly and Company Basic Information, Area Served and Competitors
Table 78. Eli Lilly and Company Major Business
Table 79. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 80. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Eli Lilly and Company Recent Developments/Updates
Table 82. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 83. Merck & Co. Basic Information, Area Served and Competitors
Table 84. Merck & Co. Major Business
Table 85. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 86. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Merck & Co. Recent Developments/Updates
Table 88. Merck & Co. Competitive Strengths & Weaknesses
Table 89. Viventia Bio Inc. Basic Information, Area Served and Competitors
Table 90. Viventia Bio Inc. Major Business
Table 91. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 92. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Viventia Bio Inc. Recent Developments/Updates
Table 94. Viventia Bio Inc. Competitive Strengths & Weaknesses
Table 95. Celgene Corporation Basic Information, Area Served and Competitors
Table 96. Celgene Corporation Major Business
Table 97. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 98. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Celgene Corporation Recent Developments/Updates
Table 100. Celgene Corporation Competitive Strengths & Weaknesses
Table 101. Spectrum Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 102. Spectrum Pharmaceuticals, Inc. Major Business
Table 103. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 104. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Spectrum Pharmaceuticals, Inc. Recent Developments/Updates
Table 106. Spectrum Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 107. Herantis Pharma Plc. Basic Information, Area Served and Competitors
Table 108. Herantis Pharma Plc. Major Business
Table 109. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 110. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Herantis Pharma Plc. Recent Developments/Updates
Table 112. Herantis Pharma Plc. Competitive Strengths & Weaknesses
Table 113. Taris Biomedical LLC Basic Information, Area Served and Competitors
Table 114. Taris Biomedical LLC Major Business
Table 115. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 116. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Taris Biomedical LLC Recent Developments/Updates
Table 118. Taris Biomedical LLC Competitive Strengths & Weaknesses
Table 119. Prometic Life Sciences Inc. Basic Information, Area Served and Competitors
Table 120. Prometic Life Sciences Inc. Major Business
Table 121. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 122. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Prometic Life Sciences Inc. Recent Developments/Updates
Table 124. Prometic Life Sciences Inc. Competitive Strengths & Weaknesses
Table 125. Telormediz S.A. Basic Information, Area Served and Competitors
Table 126. Telormediz S.A. Major Business
Table 127. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 128. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Telormediz S.A. Recent Developments/Updates
Table 130. Telormediz S.A. Competitive Strengths & Weaknesses
Table 131. Heat Biologics Basic Information, Area Served and Competitors
Table 132. Heat Biologics Major Business
Table 133. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 134. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Heat Biologics Recent Developments/Updates
Table 136. Heat Biologics Competitive Strengths & Weaknesses
Table 137. Altor BioScience Basic Information, Area Served and Competitors
Table 138. Altor BioScience Major Business
Table 139. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 140. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 141. Altor BioScience Recent Developments/Updates
Table 142. Altor BioScience Competitive Strengths & Weaknesses
Table 143. Ferring B.V. Basic Information, Area Served and Competitors
Table 144. Ferring B.V. Major Business
Table 145. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 146. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 147. Ferring B.V. Recent Developments/Updates
Table 148. Cold Genesys Inc. Basic Information, Area Served and Competitors
Table 149. Cold Genesys Inc. Major Business
Table 150. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Services
Table 151. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 152. Global Key Players of Non-muscle Invasive Bladder Cancer Therapeutics Upstream (Raw Materials)
Table 153. Non-muscle Invasive Bladder Cancer Therapeutics Typical Customers
List of Figure
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Picture
Figure 2. World Non-muscle Invasive Bladder Cancer Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Non-muscle Invasive Bladder Cancer Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Non-muscle Invasive Bladder Cancer Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Non-muscle Invasive Bladder Cancer Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Non-muscle Invasive Bladder Cancer Therapeutics Markets in 2022
Figure 27. United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Non-muscle Invasive Bladder Cancer Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type in 2022
Figure 31. Intravesical Chemotherapy
Figure 32. Intravesical Immunotherapy
Figure 33. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2018-2029)
Figure 34. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Application in 2022
Figure 36. Hospital
Figure 37. Ambulatory Surgery Center
Figure 38. Others
Figure 39. Non-muscle Invasive Bladder Cancer Therapeutics Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Related Reports
27 Feb 2023
Medical Care
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
